Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | RAB9A | P51151 | 4/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908172 | 0.89 | ALDH1A1 (0.84) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL16655883 | 0.88 | NPC1 (0.74) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL5696463 | 0.87 | ALDH1A1 (0.85) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL5696432 | 0.87 | ALDH1A1 (0.80) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL4912964 | 0.86 | NPC1 (0.80) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL5696442 | 0.85 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL420221 | 0.83 | ALDH1A1 (0.68) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL4293534 | 0.83 | MAPT (0.69) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL15647994 | 0.83 | MAPT (0.58) | ALDH1A1TSHRMAPK10HSD17B10RAB9A | |
| SCHEMBL14960451 | 0.82 | MAPT (0.71) | ALDH1A1TSHRRAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | claimed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | claimed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | claimed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | claimed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | HCCS, ALAD, HAVCR2 | ALDH1A1 271/4885TSHR 4195/4885MAPK10 2338/4885 |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | HCCS, ALAD, HAVCR2 | ALDH1A1 271/4885TSHR 4195/4885MAPK10 2338/4885 |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | ALDH1A1 499/4885TSHR 1712/4885MAPK10 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.